Cambridge based biotech T-Therapeutics has expanded its Series A round to a total of $91 million to accelerate a new class of T cell receptor based bispecific therapies. The extension underscores sustained investor confidence in next generation immunotherapies that target upstream drivers of cancer and autoimmune disease. It also reinforces the UK’s position as a key hub for high conviction life sciences financing in 2025.
Series A Extension and Investor Syndicate
The latest $32 million (€27.5 million) equity injection builds on an initial $59 million, taking the overall Series A to $91 million (€78.2 million). New backers Tencent and BGF joined the syndicate alongside existing investors Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund. The round positions T-Therapeutics among the more substantial European immuno-oncology financings this year in terms of Series A scale.
Strategic Use of Capital
T-Therapeutics will deploy the additional funding to push its pipeline of first in class TCR-CD3 bispecifics from preclinical development towards the clinic. The capital will also support exploration of new therapeutic strategies, including selective T cell subset depletion in oncology and immunology. Collectively, these programs are aimed at targeting upstream disease mechanisms with the potential for pan indication impact across multiple tumor types and autoimmune conditions.
Lead Programs in Oncology and Autoimmune Disease
The company’s lead oncology asset focuses on a pan tumor driver target that could be relevant across a range of solid tumors, rather than a single cancer type. In parallel, its flagship immunology program is a pan autoimmune bispecific designed to deliver a precision immune reset by selectively eliminating pathogenic immune cells. If successfully translated into the clinic, this approach could offer a differentiated alternative to broad immunosuppression, potentially improving both efficacy and safety for patients.
OpTiMus Platform and Bispecific Architecture
At the core of T-Therapeutics’ strategy is OpTiMus, a proprietary TCR discovery platform that can generate a vast repertoire of high specificity, fully human T cell receptors. This enables the company to access validated but historically “undruggable” intracellular targets that conventional antibody approaches struggle to reach. These TCRs are paired with engineered next generation CD3 T cell engagers, optimized for potency, safety and pharmacokinetics, to form bispecific candidates that redirect T cells against disease drivers.
Position in the European Immunotherapy Landscape
The Series A extension comes amid a broader wave of European activity in immuno-oncology and immunology, with companies such as France’s Adcytherix and Spain’s Adaptam Therapeutics also attracting fresh capital in 2025. Together, these financings highlight persistent investor appetite for platforms that can reshape immune responses against cancer and immune mediated disorders. Within this context, T-Therapeutics’ cumulative €78.2 million Series A represents a significant slice of visible funding flowing into European immune targeting platforms this year.
Backing, Leadership and Execution Focus
Existing investors emphasize that they co founded T-Therapeutics to push the boundaries of bispecific technology, with the new capital expanding the company’s ability to pursue T cell subset depletion alongside oncology programs. They argue that the platform is now well positioned to unlock targets previously considered out of reach, spanning both cancer and autoimmune indications. BGF highlights the leadership team’s track record in building successful drug discovery businesses and translating complex science into clinical stage assets, a factor viewed as critical as the company moves toward first in human studies.
With $91 million now committed, T-Therapeutics has strengthened its financial base to advance its TCR-CD3 bispecific pipeline into the next phase of development. The combination of a differentiated discovery platform, pan indication targets and a deep syndicate of specialist investors provides a clear pathway toward clinical validation. The company’s progress will be closely watched as it attempts to convert high specificity, T cell based science into transformative therapies for patients with cancer and autoimmune disease.